Home > Insider Trading > Filing (0001209191-18-004394)

Filing Details

Accession Number:: 0001209191-18-004394
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-01-18 18:57:55
Reporting Period:: 2018-01-16

Accepted Time:: 2018-01-18 18:57:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704234	Declan Doogan	C/O Biohaven Pharmaceuticals 234 Church Street New Haven CT 06510		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2018-01-16	37,033	$26.59	1,487,027	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-16	1,834	$27.07	1,485,193	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-17	23,726	$26.19	1,461,467	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-17	37,530	$26.84	1,423,937	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-18	4,546	$26.71	1,419,391	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-18	5,618	$27.87	1,413,773	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-18	17,671	$28.71	1,396,102	No	4	S	Indirect	By The Declan Doogan 2014 Trust
Common Shares	Disposition	2018-01-18	100	$29.22	1,396,002	No	4	S	Indirect	By The Declan Doogan 2014 Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust
No	4	S	Indirect	By The Declan Doogan 2014 Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	463,913	Direct

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 - $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes 346,002 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules (the "Distribution").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 - $26.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.64 - $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 - $28.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.21 - $29.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4.
Represents shares received directly by the Reporting Person in the Distribution.